# Polycystic Ovarian Syndrome Market

> Polycystic Ovarian Syndrome Market Research Report: Information by Drug Class (Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agents, Antidepressants, Anti-Obesity, and Others.), By Route of Administration (oral and parenteral), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), By Application (Military , Civilian)By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.61%
- **2024:** $ 5,497.24 Million
- **2025:** $ 5,839.82 Million
- **2035:** $ 10,130.72 Million
- **Key Players:** Companies such Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon, Novo Nordisk A/S, Bayer AG, Pfizer Inc, Sanofi, AstraZeneca are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/4834-CR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/polycystic-ovarian-syndrome-market-6295

---

## Market Summary

## **Global Polycystic Ovarian Syndrome Market Overview**

Polycystic Ovarian Syndrome Market Size was valued at USD 2.93 Billion in 2023. The Polycystic Ovarian Syndrome industry is projected to grow from USD 3.08 Billion in 2024 to USD 4.26 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032).The rising frequency of diabetes, the use of less invasive surgery, and the rise in female hormonal diseases are the key market drivers enhancing the market growth.

For September 2023, Ulike, the market leader in home IPL hair removal, is supporting Polycystic Ovary Syndrome (PCOS) warriors for PCOS Awareness Month (September) through their We See You campaign. This has been Ulike’s mission for years: raising Hirsutism awareness as well as giving patients alternatives that are sympathetic to it for a category of women who have PCOS and experience undesired growth of body and facial hair in particular. The company’s most recent introduction, Air3, boasts advanced patented techniques that enable smooth and effective hair removal.

Thus, the brand combines science with user-centered design, ensuring both safety and effectiveness and providing visible results within a short time span of three weeks only. In addition to that, long-lasting smoothness also pleases PCOS users since the latter normally experience faster hair re-growth than an average woman does.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) wishes to announce in August 2023 that its child company, BioSyent Pharma Inc., has made its first shipments of Inofolic® into the Canadian markets. Living with PCOS can find myo-inositol with folic acid in one special soft-gel capsule called Inofolic®, A natural health product designed for females suffering from polycystic ovarian syndrome-PCOS). As many as 1.4 million Canadian women have endocrine disorders, i.e., a syndrome known as polycystic ovary syndrome (PCOS).

Its causative agents concerning this include insulin resistance problems leading to infertility, menstrual dysfunction, among others, acne outbreaks, and hirsutism-related skin effects caused by excess body hair growth over men’s faces or chins.

Rachel Blank did not always get along with hormones in June 2021; she had a history with them, too. After she left General Catalyst, where Ms Blank worked as an investor to join Ro, a startup they had been backing from the seed stage, she was in charge of growing Rory. Nonetheless, her decision to leave the director’s role at a health technology unicorn valued at $5 billion and set up her own company for women’s hormonal health. Today, the startup is coming out of stealth with millions in venture-backing and more than 35,000 women in its community.

An early-stage New York-based startup called Allara looks to help women struggling with polycystic ovary syndrome (PCOS) better manage it. It leads to irregular periods or difficulty getting pregnant in females, as well as acne and obesity with unwanted hair growth. And it is not uncommon, affecting around one out of every ten women who can have children.

## **Polycystic ovarian syndrome Market Trends**

An increase in polycystic ovarian syndrome prevalence, patient population awareness, and the use of combination therapy drives the growth of the polycystic ovarian syndrome treatment market. Additionally, the market growth is influenced by the ease of access to polycystic ovarian syndrome therapies, increased demand for polycystic ovarian syndrome drugs, and technological developments for cancer screening. However, the absence of authorized treatments and the unclear pathophysiology and etiology of the polycystic ovarian syndrome are expected to restrain market expansion.

Additionally, throughout the anticipated time, the emerging countries' untapped potential offers profitable chances for the expansion of the polycystic ovarian syndrome treatment market. However, the absence of specialized therapy for polycystic ovarian syndrome disease is anticipated to impede the expansion of the industry. The need for polycystic ovarian syndrome treatment drugs is anticipated to increase as polycystic ovarian syndrome becomes more common. For instance, according to the Centers for Disease Control and Prevention, the polycystic ovarian syndrome affects 6 to 12% (or as many as 5 million) of American women of reproductive age.

It is one of the most prevalent reasons for female infertility. Due to the rising prevalence of co-morbid illnesses, including diabetes and obesity, more people have PCOS. Thus, this factor is driving the market CAGR.

Over the projected period, it is also anticipated that increasing spending on R&D activities and the release of innovative medications would spur market expansion for pharmaceuticals treating polycystic ovary syndrome. However, a shortage of FDA-approved medications, a lack of polycystic ovarian syndrome awareness in developing nations, and rising adverse effects from generic medications might restrain market expansion throughout the projection period.

The market is anticipated to be driven by several government and private sector efforts to raise awareness of the illness. For example, in June 2020, research funded by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Diabetes and Digestive and [Kidney Diseases](../../../reports/chronic-kidney-disease-market-5744), titled "Different subtypes of polycystic ovarian syndrome with new genetic associations: An unsupervised, phenotypic clustering analysis," revealed that polycystic ovary syndrome might have at least two distinct subtypes. Thus, it is anticipated that this aspect will accelerate polycystic ovarian syndrome  market revenue globally.

## **Polycystic Ovarian Syndrome Market Segment Insights**

### **Polycystic Ovarian Syndrome Diagnosis Insights**

Based on Diagnosis, the global polycystic ovarian syndrome market segmentation includes a pelvic examination, ultrasound, and blood tests. The ultrasound segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032.  ovaries condition and the thickness of your uterus' lining may be examined with an ultrasound. Your vagina receives a transducer, which resembles a wand. Sound waves released by the transducer are converted into visuals on a computer screen.

**Figure1: Polycystic Ovarian Syndrome Market, by Diagnosis, 2023 & 2032 (USD Million)\**Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Polycystic Ovarian Syndrome Treatment Insights**

The global polycystic ovarian syndrome market segmentation, based on Treatment, includes Oral [Contraceptives](../../../reports/contraceptive-drugs-market-1276), Antiandrogens, Insulin Sensitizing Agent, Antidepressant, Anti-Obesity, Surgery (Ovarian Wedge Resection and Laparoscopic Ovarian Drilling). The surgery segment held the majority share in 2022 in the global Polycystic ovarian syndrome market data One of the most frequent operations surgeons perform in life-threatening situations is laparoscopic ovarian drilling (LOD). Since polycystic ovarian syndrome is a key contributing factor to women's reproductive issues and treatment response deteriorates over time, abdominal surgery using a thin microscope is highly preferred globally.

According to research published in the Cochrane Library in July 2020 under the title "Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome," if the chance of a live birth following medical ovulation induction alone is 42%, the chance of a live birth following LOD is between 28% and 40%. According to the study, laparoscopic drilling is highly likely to succeed in women, which is why it is the procedure of choice. Patients are drawn to this surgical technique due to its simplicity of illness treatment and cost-effectiveness.

As a result, it is predicted to have a sizable share throughout the projection period.

### **Polycystic ovarian syndrome End-user Insights**

Based on End-user, the global polycystic ovarian syndrome market segmentation includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the Polycystic ovarian syndrome  market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. In 2021, Ambulatory Surgical Centers ranked second in terms of market size. Due to the present rise in polycystic ovarian syndrome incidence and the rising number of procedures performed in hospital settings, the hospital segment is predicted to develop at the quickest rate. Polycystic ovarian syndrome is often diagnosed and treated in hospitals.

Since no one test can be used to precisely identify polycystic ovarian syndrome (PCOS), clinicians must determine this for patients with the polycystic ovarian syndrome.

### **Polycystic Ovarian Syndrome Regional Insights**

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. In North America, the Polycystic ovarian syndrome market accounted for USD 1.3 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. One of the major reasons driving the market growth in North America is the rise in polycystic ovarian syndrome cases due to rising rates of obesity and overweight. In addition, more people are becoming aware of the advantages of routine checkups, increasing the number of new cases detected here each year.

The United States dominates the North American Polycystic ovarian syndrome market with the highest revenue share. This market is expanding mostly due to this nation's huge number of polycystic ovarian syndrome sufferers. Furthermore, the U.S.'s ability to attract large market participants like Merck, Abbott, and BMS would substantially impact the nation's ability to generate income.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: POLYCYSTIC OVARIAN SYNDROME  MARKET SHARE BY REGION 2021 (%)**Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Asia Pacific Polycystic ovarian syndrome Market together make up most of the population in the Asia Pacific region. As a result, the Region's polycystic ovarian syndrome treatment market has tremendous development potential due to the presence of a sizable target patient pool. The governments of these nations are concentrating on reducing the rising prevalence of polycystic ovarian syndrome by implementing initiatives that promote the Diagnosis, Treatment, and necessary lifestyle change of this syndrome. These initiatives raise public awareness of the polycystic ovarian syndrome and its hazards, including the emergence of insulin resistance, obesity, and occasionally infertility.

Shortly, the Asia Pacific market is anticipated to be driven by these reasons. Further, the China Polycystic ovarian syndrome  market held the largest market share, and the India Polycystic ovarian syndrome  market was the fastest growing market in the region.

Due to improvements in healthcare infrastructure, an increase in the number of target populations, a growing R&D sector, an increase in healthcare reforms, and technical developments in the healthcare field, Europe Polycystic ovarian syndrome Market will have the third-highest growth during the projected period of 2021. Moreover, U.K. Polycystic ovarian syndrome Market held the largest market share, and the Germany Polycystic ovarian syndrome  Market was the fastest-growing market in the Region.

**Polycystic ovarian syndrome  Key Market Players & Competitive Insights**

Major market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for cervical fusion. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their global presence. To grow and remain in a market that is becoming more and more competitive, polycystic ovarian syndrome industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the main business tactics used by the Polycystic ovarian syndrome industry to serve customers and increase the market sector. The Polycystic ovarian syndrome industry has recently given medicine some of the most important advantages. The Polycystic ovarian syndrome market major player such as Bayer AG, AstraZeneca plc, Abbott, Biocinese, Catalysis, S.L., Crinetics Pharmaceuticals, Inc., Sanofi, Eugonia, EffRx, Inc., Ferring Pharmaceuticals, Inc., Merck KGaA, Bristol-Myer Squibb Company, Neurocrine Biosciences, Inc., Reliance Life Sciences Pvt. Ltd.

Pfizer, Inc., Novartis AG, and Shire Plc., and others are working to expand the market demand by investing in research and development activities.

Founded in 2013, the American biopharmaceutical business AbbVie is publicly listed. It began as an Abbott Laboratories spin-off. Abbvie was conducting a clinical study in women with polycystic ovarian syndrome to determine the safety and effectiveness of the drug Elagolix January 2020. Elagolix's safety and effectiveness in treating women with Polycystic ovarian syndrome are now being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study being carried out by the company (PCOS).

One of the biggest pharmaceutical firms in the world is Bayer AG, a global German pharmaceutical and biotechnology corporation. • In January 2020, Evotec S.E. and Bayer AG announced the start of a new, multi-target, five-year cooperation with Celmatix Inc. to develop several clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market for the whole forecast period. In January 2020, Abbvie will begin a clinical trial employing the drug Elagolix, which is being tested for both safety and effectiveness in treating Polycystic ovarian syndrome in female patients.

Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome are being examined in the Phase 2 multicenter, double-blind, randomized, placebo-controlled study that the company is now doing.

**Key Companies in the polycystic ovarian syndrome market include**

**Polycystic Ovarian Syndrome Industry Developments**

## **Polycystic Ovarian Syndrome Market Segmentation**

### **Polycystic Ovarian Syndrome Diagnosis Outlook**

### **Polycystic Ovarian Syndrome Treatment Outlook**

### **Polycystic Ovarian Syndrome End-User Outlook**

### **Polycystic ovarian syndrome Regional Outlook**

## Market Drivers

### Improved Ultrasound Technology

Advancements in ultrasound technology have significantly contributed to the growth of the Polycystic Ovarian Syndrome Market by enhancing diagnostic accuracy and patient management. High-resolution transvaginal ultrasounds enable healthcare providers to detect ovarian cysts and characteristic morphological features associated with PCOS more precisely.
 

- For instance, the use of 3D ultrasound imaging allows for detailed visualization of ovarian volume and follicle count, which are critical parameters in PCOS diagnosis according to the Rotterdam criteria. Such technological improvements facilitate early detection, enabling timely intervention and personalized treatment plans.

### Rising Prevalence of Insulin Resistance & Metabolic Comorbidities

The rising prevalence of insulin resistance and associated metabolic comorbidities is a significant driver of the global Polycystic Ovary Syndrome (PCOS) market. Insulin resistance is a major syndrome, affecting an estimated 60% to 95% of women with PCOS who are overweight and roughly 35% of those who are lean, according to the Journal of Clinical Medicine.
 
This metabolic link has shifted the treatment paradigm from purely reproductive care to long-term chronic disease management.

## Future Outlook

The Polycystic Ovarian Syndrome Market size is projected to reach USD 10,130.72 million by 2035, growing at a CAGR of 5.61%, driven by increasing demand for high-performance computing and enhanced security features.

**New opportunities:**

- Growing Telehealth Specialization. Point-of-Care (POC) Testing.

By 2035, the global market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Drug Class: Oral Contraceptives (largest market) vs Insulin Sensitizing Agents (fastest growing)

Based on drug class, the Polycystic Ovarian Syndrome Market has been segmented into Oral Contraceptives, Antiandrogens, Insulin Sensitizing Agents, Antidepressants, Anti-Obesity, and Others. Insulin Sensitizing Agents further segmented into Biguanides, Thiazolidinediones (TZDs), and Others. Anti-obesity further segmented into GLP-1 Receptor Agonists, Lipase Inhibitors, and Others. The Oral Contraceptives segment held the largest market share in 2025 at 34.8%, and the Insulin Sensitizing Agents segment is the fastest growing segment during the forecast period.

### By Route of Administration: Oral (largest market) vs parenteral (fastest-growing)

Based on route of administration, the Polycystic Ovarian Syndrome Industry has been segmented into oral and parenteral. The oral****segment held the largest market share in 2025 at 81.6%, and the same segment is the fastest growing segment during the forecast period.

### By Distribution Channel: Retail pharmacies (largest market) vs Hospital pharmacies (fastest-Growing)

Based on distribution channel, the Polycystic Ovarian Syndrome Market has been segmented into Hospital pharmacies, Retail pharmacies, and Online pharmacies. The Retail Pharmacies segment held the largest market share in 2025 46.9%, and the Online Pharmacies segment is the fastest growing segment during the forecast period.

## Regional Market Share Analysis

### North America**:**Advanced healthcare systems

North America dominates the PCOS market, holding 32.56% share in 2024 and valued at $0.44 billion in 2025. High prevalence (around 10-15% in U.S. women), advanced healthcare systems, and strong reimbursement policies drive this leadership. Government initiatives like women's health programs and pharma investments boost adoption of treatments such as oral contraceptives and insulin-sensitizers. The U.S. contributes most, supported by clinical trials and major players like Pfizer. Projections indicate sustained growth at above-global averages through 2032.

- According to the CDC, PCOS affects nearly 5 million women of reproductive age in the United States, while WHO estimates global prevalence ranges between 8% and 13%.

### Europe: Strong enhance treatment access and standardization

Europe Polycystic Ovarian Syndrome Market size was valued at USD 1649.17 million in 2024, making it the second-largest regional market with a 30% share. Europe captures a significant portion, fueled by high prevalence (11.7% regionally) in countries like the UK (1 in 5 women affected), Germany, and France. Growing healthcare expenditure and EU initiatives like SPIOMET4Health enhance treatment access and standardization. Focus on metabolic comorbidities and fertility care supports market expansion, with emphasis on combination therapies. The region trails North America but grows steadily via public awareness campaigns and specialist clinics. By 2032, Europe is expected to maintain robust shares in therapeutics.

- According to WHO Europe and regional clinical estimates, PCOS prevalence in Europe reaches approximately 11.7%, with some countries such as the UK reporting that nearly 1 in 5 women are affected.

### Asia Pacific: Rising incomes improve diagnostics

APAC is the fastest-growing region, projected to outpace others due to massive patient pools and urbanization. India and China report 20-25% urban prevalence, with China holding 50.3% of East Asia's share. Investments in infrastructure, awareness drives, and rising incomes improve diagnostics like ultrasounds and blood tests. Lifestyle shifts exacerbate cases, spurring demand for affordable generics.

### South America: Protection of hospitals and ambulatory centers drives treatments

South America, part of Latin America, grows modestly amid increasing diagnosis rates in Brazil and Mexico. Prevalence mirrors global trends (10-15%), boosted by obesity epidemics. Improving access to hospitals and ambulatory centers drives treatments, with pharma expansion aiding generics. Economic volatility hampers pace, but women's health programs signal potential. The region anticipates steady CAGR, supported by regional trade in drugs.

### Middle East & Africa: Emerging strategic waterways protection requirements

MEA faces high PCOS burden, with Eastern Mediterranean prevalence at 15.1%—the world's highest. Emerging markets like GCC countries and South Africa grow via pharma penetration and urbanization. Challenges include limited diagnostics and awareness, but oil wealth funds healthcare upgrades in GCC. Fertility focus amid cultural priorities aids therapeutics uptake. Gradual expansion expected as infrastructure improves, though shares remain smallest globally.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Polycystic Ovarian Syndrome Market. The Polycystic Ovarian Syndrome market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.
 
The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major players in the global market Include Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon, Novo Nordisk A/S, Bayer AG, Pfizer Inc, Sanofi, AstraZeneca, strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

August 2025: Bayer AG focuses on strengthening its position in the women’s health and pharmaceutical sector by investing heavily in research and development to introduce innovative therapies for conditions such as endometriosis and other hormonal disorders. The company emphasizes expanding its women’s health product portfolio, particularly through hormonal treatments and long-term therapeutic solutions.

April 2025: Pfizer’s key strategies focus on strengthening its position as a global leader in biopharmaceutical innovation. The company continues to invest heavily in research and development, with a strong emphasis on oncology, vaccines, immunology, rare diseases, and next-generation platforms such as mRNA technology. Strategic partnerships and acquisitions remain central to its growth approach, as seen in collaborations with BioNTech for vaccines and the acquisition of Seagen to boost its oncology portfolio. Pfizer is also diversifying beyond COVID-19 products by expanding into biologics, gene therapies, and precision medicine to ensure long-term revenue stability.

March 2025: Sanofi focuses on strengthening its position in the global biopharmaceutical market through continuous investment in research and development to develop innovative therapies across multiple therapeutic areas, including women’s health and rare diseases. The company emphasizes strategic collaborations, partnerships, and acquisitions with biotechnology firms and research organizations to accelerate drug discovery and expand its product pipeline. 

## Report Scope

| Market Size 2024 |  5,497.24 (USD Million) |
| --- | --- |
| Market Size 2025 | 5,839.82 (USD Million) |
| Market Size 2035 | 10,130.72 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 5.61% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon, Novo Nordisk A/S, Bayer AG, Pfizer Inc, Sanofi, AstraZeneca. |
| Segments Covered | By Drug Class By Route of Administration By Distribution Channel |
| Key Market Opportunities | Growing Telehealth Specialization Expansion on Point-of-Care (POC) Testing. |
| Key Market Dynamics | Rising Prevalence of Insulin Resistance & Metabolic Comorbidities Improved Ultrasound Technology Expanding Therapeutic Scope Beyond Reproductive Symptoms. |
| Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. |

## Frequently Asked Questions

**Q: How much is the Polycystic Ovarian Syndrome Market?**
A: USD 10,130.72 Million (2035) is the Polycystic Ovarian Syndrome Market

**Q: What is the growth rate of the Polycystic Ovarian Syndrome Industry?**
A: 5.61% is the growth rate of the Polycystic Ovarian Syndrome Industry.

**Q: Which region held the largest market share in the Polycystic Ovarian Syndrome Market?**
A: North America held the largest market share in the Polycystic Ovarian Syndrome Market.

**Q: Who are the key players in the Polycystic Ovarian Syndrome Market?**
A: Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon, Novo Nordisk A/S, Bayer AG, Pfizer Inc, Sanofi, AstraZeneca are the key players in the Polycystic Ovarian Syndrome Market.

**Q: Which Distribution Channel had the largest market share in the Polycystic Ovarian Syndrome Industry?**
A: Retail pharmacies had the largest market share in the Polycystic Ovarian Syndrome Industry.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/polycystic-ovarian-syndrome-market-6295*